Zealand Pharma, a leading biotechnology company focused on discovering and developing innovative peptide-based medicines, has announced that its partner, Boehringer Ingelheim, will present positive results from a Phase 2 clinical trial evaluating survodutide in patients with MASH (Metabolic Associated Steatohepatitis) at the upcoming European Association for the Study of the Liver (EASL) conference.
Survodutide, a novel long-acting GLP-1/GCG dual agonist, has shown promising efficacy and safety in the treatment of MASH, a serious liver condition associated with metabolic disorders such as obesity and type 2 diabetes. The positive Phase 2 results demonstrate the potential of survodutide as a groundbreaking therapy for patients suffering from this debilitating condition.
The presentation of these findings at the prestigious EASL conference underscores the significance of the collaboration between Zealand Pharma and Boehringer Ingelheim in advancing innovative treatments for metabolic and liver diseases. The companies are committed to further developing survodutide as a potential game-changer in the management of MASH and improving the lives of patients worldwide.
